Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
Open Access
- 25 January 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 12 (4), 401-408
- https://doi.org/10.1093/neuonc/nop047
Abstract
Immunostimulating oligodeoxynucleotides containing CpG motifs (CpG-ODN) have shown promising efficacy in cancer models when injected locally. In a phase I clinical trial, intratumoral infusions of CpG-ODN in glioblastoma (GBM) patients were well tolerated at doses up to 20 mg. This phase II trial was designed to study the efficacy of a local treatment by CpG-ODN in patients with recurrent GBMs. Patients with recurrent GBM occurring at least 3 months after radiotherapy, and previously treated with 1 or 2 regimens of chemotherapy received 20 mg of CpG-ODN (CpG-28) by convection-enhanced delivery. The primary endpoint was the percentage of patients without tumor progression 6 months after inclusion. Secondary endpoints were tolerance, survival, and radiological response. Thirty-four patients were enrolled in two centers between November 2004 and March 2006. Thirty-one patients received CpG-ODN treatment. The progression-free survival (PFS) at 6 months was 19%. One partial response and 3 minor responses were observed. The median overall survival was 28 weeks. Eight patients (24%) were alive 1 year after inclusion and 5 patients (15%) were alive after 2 years. Treatment was usually well tolerated. As reported previously, the most common toxicities were lymphopenia, mild fever, seizures, and transient neurological worsening. Despite a few cases showing a radiological response, CpG-28 showed modest activity on the 6-month PFS in this patient population. The molecular or clinical characteristics of a subgroup of patients that could potentially benefit from such an approach remain to be defined.Keywords
This publication has 27 references indexed in Scilit:
- Glucocorticoids increase CD4+CD25highcell percentage and Foxp3 expression in patients with multiple sclerosisActa Neurologica Scandinavica, 2009
- Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotidesCurrent Oncology Reports, 2004
- Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain TumorsJournal of Neuro-Oncology, 2003
- CpG-oligonucleotides for cancer immunotherapy review of the literature and potential applications in malignant gliomaFrontiers in Bioscience-Landmark, 2003
- A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.2002
- Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human CellsThe Journal of Immunology, 2001
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.2000
- MethyLight: a high-throughput assay to measure DNA methylationNucleic Acids Research, 2000
- Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.1999